ICS/LABA Combination With Integrated Dose Counter and Smartphone APP to Improve Asthma Control

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Poor adherence to asthma controller medication may link to poor asthma outcome. A metered dose device with built-in dose counter helps physicians to monitor drug compliance in asthma patients. Mobile-phone based self management opens a window for better asthma control. The present study aims to investigate the relationship between the adherence to controller medication of combined inhaled corticosteroid/long acting beta2-agonists, assessing by integrated dose counter, and the level of airway inflammation and asthma control. Moreover, the investigators also use a new asthma self-management Apps to enhance drug compliance. With the application of the new, easily available tools, the investigator expect to increase adherence rates, and hence, to reduce airway inflammation and improve the level of asthma control.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Veterans General Hospital, Taiwan
• Treatments: Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Salmeterol Xinafoate

Criteria

Inclusion Criteria:

1. Symptomatic asthmatics free of controller medication for at least 3 months

2. Aged from 20 to 70 years

3. Life-long smoking index < 10 pack-years

Exclusion Criteria:

1. COPD, clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known specific pulmonary disease.

2. A chest X-ray indicating diagnosis other than asthma that might interfere with the study.

3. Major disease abnormalities are uncontrolled on therapy.

4. Alcohol or medication abuse.

5. Patients had lower respiratory tract infections or received systemic steroid in the 4 weeks prior to the commencement of study.

6. Unable or unwilling to comply with all protocol

7. Unable to use Smartphone